FACIO THERAPIES
Facio Therapies is a single-minded pharmaceutical company. Their focus is entirely on one disease: FSHD – short for facioscapulohumeral dystrophy. Despite over 35 years of basic research into FSHD, there is no approved therapy. In the early teens of this century, the consensus emerged that FSHD is caused by the presence in skeletal muscle of a protein that should not be there. That scientific breakthrough sparked hope throughout the FSHD community, but has proven difficult to translate into r... eal progress towards a therapy. In September 2014, three prominent members of the FSHD community decided to take matters into their own hands. Kees van der Graaf (Netherlands), a former member of the Board of Directors of Unilever; Bill Moss AO, a former executive director of the Australian investment bank, Macquarie Group; and Neil Camarta (Canada), President and CEO of Western Hydrogen Ltd and a former executive at Shell, jointly founded Facio Therapies. Kees’s elder son, Bart, has FSHD. Bill and Neil have FSHD themselves.
FACIO THERAPIES
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Leiden, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.facio-therapies.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Nginx Sitelinks Search Box
Current Advisors List
Current Employees Featured
Official Site Inspections
http://www.facio-therapies.com Semrush global rank: 7.94 M Semrush visits lastest month: 410
- Host name: nano.texteditor.si
- IP address: 168.235.65.207
- Location: Atlanta United States
- Latitude: 33.8336
- Longitude: -84.3797
- Metro Code: 524
- Timezone: America/New_York
- Postal: 30305
More informations about "Facio Therapies"
Facio Therapies Company Profile 2024: Valuation, …
Facio Therapies General Information Description. Operator of a biology-oriented company based in Leiden, Netherlands. The company specializes in …See details»
Facio BT – Novel Therapies for FSHD
Jul 12, 2024 Facio Biotherapies is an Australian disease centric biotechnology company dedicated to pioneering innovative treatments for FSHD—a progressive muscle-weakening …See details»
Facio Therapies - Crunchbase Company Profile & Funding
Facio Therapies is a single-minded pharmaceutical company. Their focus is entirely on one disease: FSHD – short for facioscapulohumeral dystrophy. Despite over 35 years of basic …See details»
Facio Therapies – FSHD
Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle …See details»
Facio Therapies B.V. - Life-Sciences-Europe.com
Jan 1, 2014 Facio Therapies, established in 2014, is a Netherlands-based company with a single focus - to overcome FSHD by developing a causal therapy that restores the repression …See details»
Facio Therapies: Contact Details and Business Profile - RocketReach
Facio Therapies, established in 2014, is a Netherlands-based company with a single focus - to overcome FSHD by developing a causal therapy that restores the natural repression of muscle …See details»
Facio Therapies - VentureRadar
"Facio Therapies has been established with a single focus – to find a cure for FSHD. FSHD (in full: facioscapulohumeral dystrophy) is a muscle wasting disease that generally progresses …See details»
Facio Therapies – FSHD
Facio Therapies is a biotech that has a single focus on developing therapies for FSHD. As an investor of Facio Therapies, the Facio Executive Team come to Sydney to update the FSHD …See details»
Facio Therapies - Products, Competitors, Financials, Employees ...
About Facio Therapies. Facio Therapies, established in 2014, is a Netherlands-based company with a single focus - to overcome FSHD by developing a causal therapy that restores the …See details»
Facio Therapies Company Profile - Office Locations, Competitors
Facio Therapies is a pharmaceutical company focused on facioscapulohumeral dystrophy (FSHD). It is engaged in the development of an FSHD screening platform and drug candidates …See details»
Facio Therapies - Company Profile - Tracxn
Oct 18, 2024 Facio Therapies ranks 403rd among 590 active competitors. 218 of its competitors are funded while 135 have exited. Overall, Facio Therapies and its competitors have raised …See details»
Facio Therapies - Overview, News & Similar companies - ZoomInfo
Facio Therapies, established in 2014, is a Netherlands-based company with a single focus - to overcome FSHD by developing a causal therapy that restores the natural repression of muscle …See details»
Facio Therapies - Leiden, Netherlands - bionity.com
Apr 30, 2015 Facio Therapies, founded in 2014, is a Netherlands-based company focused on curing FSHD by developing a causal therapy that suppresses the toxic protein DUX4. Facio is …See details»
Facio Therapies is a... - FSHD-Global Research Foundation
Apr 6, 2020 Facio Therapies is a biotech that has a single focus on developing therapies for FSHD. As an investor of Facio Therapies, the Facio Executive Team come to Sydney to …See details»
Facio Therapies CEO and Key Executive Team | Craft.co
Facio Therapies's key executives include Kees van der Graaf and 4 others. Kees van der Graaf. Chairman. Joris de Maeyer. CEO. Frank Niemöller. CFO. Ria Broekgaarden. Director …See details»
Facio Therapies - LinkedIn
Facio Therapies | 223 abonnés sur LinkedIn. One Disease. Multiple Solutions. | We are a biology-oriented company founded by people living with facioscapulohumeral dystrophy (FSHD), a …See details»
Facio Therapies - Raised $3.12M Funding from investors - Tracxn
Aug 17, 2021 Facio Therapies has raised a total funding of $3.12M over 1 round. Their latest funding round was of $3.12M on Oct 01, 2015 .See details»
Iktos and Facio Therapies Announce Collaboration to Use AI for …
May 11, 2021 Since inception, Facio has raised close to €28M in equity funding from FSHD-affected families, their friends, FSHD foundations, and Facio’s drug discovery partner, Evotec.See details»
Facio Therapies Presentation February 2020 - YouTube
Apr 6, 2020 Facio Therapies is a biotech that has a single focus on developing therapies for FSHD. As an investor of Facio Therapies, the Facio Executive Team come to Sy...See details»
Evotec Partner Facio Therapies achieves first-ever in vivo proof of ...
Evotec partner Facio Therapies (“Facio”) announced today that oral treatment with one of Facio’s lead candidates results in significant reduction of the human muscle-toxic DUX4 protein in …See details»